Hyaluronans: ls Ctinicat Effectiveness - Crespine Gel

Hyaluronans: ls Clinical Effectiveness Dependent on Molecular Weight?
52. Êspallargues M, Pons JM. Eficacy and safety of viscosupplementation with
hylan G-F 20 for the treatment of knee osteoarthriiis: a systematic roview. Int
J ?â*nolAssess Health Care. 2003;.1 9:41 -56.
53. Wang CI Un J, Chang CJ, Un Yl Hou $M. Therapeutic effects of hyaluronic
acid on osteoarthdtis of the knee. A meta-analysis of randomized controlled
lnds. J Bar,e Jaint Sury Arn.2004;86:538-545.
54. Lo GH, Lavalley M, McAlindon 1 fuison DT. lntra-articular hyaluronic acid in
treatment ot knee osteoa.thritis: a meta-anâysis. JAMA 2003;290:3115-
3121.
55. Bellamy N, Campbell J, Robinson V Gee T, .Boume R, Wells G.
\Iscosupplernentation for tie tr€atment of ostooarthritis of the knee.
Cnchwle '€,tabase Syst Reu æ05;Apr 18iCDOt5321.
56. Wobig M, Bach G, Beks q et al. The fole of elastoviscosity in the effcaey of
viscosup$enientalist for osteoarthritis of the knee: a compâison of hylan G-
F 2O and a lower-molecular-ra;eight hyaluronan. Clin Ther. 1999;21:1549-
1562.
57, Allard S, O'Regan M. The role of elastoviscosity in the eTficacy of viscosupplementation
irr osieoarthritis of the knee: a comparison o1 hy{an ô-F 20 and a
lower-molecuf ar-weighl hyaluronan. Clin Thed 2AAO;22:792-7 95.
58. Pdtchard CH, Sripadâ R Bankes e Srnith D, Schneider D. A retrospective
comparison oT the effcacy and tolerability of sodium hyaluronate and hylan G-
F 20 in the treatment ot osteoarthritis of the knee. J Musculoskelet Res.
2æ2i6]'197-245.
59. Moskowitz R. Comrnentary onPritchard et al comparati\e relospective study
ot hylan G-F 20 and ssdium hyaluro!1ale. J Mrcculoskdetalfres. 2004;7:v-vii.
60. Brown DJ, Wood EV Hannah HM, Rao VS, Tۉnby.D. Prospeclive comparison
of sodium hyaluronate and hy{an G-F 20 in a clinical practice: comment
on the concise communicaTion by Manens Iletterl. e16;i11t p1r**.
2004;50:1697-1698.
61. Garcia B. A comparative study: pssdoseptic reactions to Synvisc and not
Hyalgan injections. Presented at Annual Me€ting ofthe Arnerican Academy
of Orthopaedic Sugêons; Mârch 1A-14, 2m4: San Francisco, Calif.
62. Richardson M, Larsen KM, Moore KD, Droege l- Hæld DC. Êandomized
safety ând eff,cacy compafison of hylan G-F 20 and sodium hyaluronate in
knee osteoarth.itis: a safety distinction ldetter]. J Bone Joint Surg Am. June
30, 2m4. Availâble at http://vwwv.ejbjs.or0/cgileletters/84Æl1 619. Accessed
March 10.2005.
63. Hamburger Ml, Brandt L, Bennett R, et â1. Retrospective comparative anal!€is
of the safety and e{ficacy of infaa{icular hplun3nan therapies in clinical prac-
428 The American Journal of Orthopedicso
tice. Ost€oarlh/ûs Çattilage. !@{;12:S146.
64. lGr'lsson J, Sjogen LS, Lrhmânder LS. Cornparison ol iwo hyaluronan drugs
and daæbo in @ients with knee osteoaûfitis. A controllod, mndomized, doubfe-blind,
parâllef-design multicgltre study. RTetmatobgy. 2ffi2;41:j240-1248.
65. Kirschner M. Marshall, D.A. double-blind randomized controlled trial compâring
alternate torms of high molecular weight hyaluronan for the trsatment
of osteoarthritis of the knee. OsteoArthritis and Cartilage.
2006;14:154*162.
ô6. ACB Subcommiitee on Osteoarthritis Guidelines. Recommendations for the
medical manâgement of osteoarthritis o{ tfre hip and knee: 2æ0 updâ1e.
Attllri(s Rheum. 2000:43:1 905-1 91 5.
67. Hamburger Ml, Lâkhanpal S, Mooaf PA, Osler D. Intra-aftjçular hyaluronans:
a review of product-specific safety profiles. Semin' Arthitis Rheum.
2003;32:296€09.
68. Bucher W, Otto I Hamburger Ml. Difterentlation of hyaluronate products by
qualiiative diffsence in their immunog*ricfu in rabbits; possible mechanism
tor prcduci-specific severe adverse reactions? Arthritis Rheum.
2N2:46:,2543-2544.
69. Bâlazs Ë, Leschiner A, Larsen N, Band B inenTors; Eornatrix lnc, assigneo.
Hylan preparaiion and melhod of recovery ihereof from animâl tissues. US
patent 5,099,013. 1992.
20. Sct*avinato A, Finæso M, Cortivo fi, Abatangelo G. Comparison of the effects
of intra-aniculâr injections of hyalurcnan and its chemically cross-linked dedvative
(hylan G-F20) in normal rabbit knee joints. Clin F:p Rheumatal.
2N2;20:445454.
7.1. Goldberg VM, Couus RD. Pseudoseptic ræctions to hylan viscosupplementation:
diagnæis and ?eâtment. C[n Adwp 2A04;419134-137.
72. Jones KB, Patd PB Deyoung BR, Budaralter JA. Viscosupplemêntation
pssjdotumor. A case rço*. J Sorn Joint Surg 41'n. 2005;87:1113- 1119.
73. Sasaki M, Miyazaki Y Takahashi T. Hylân G-F 20 induces delayed foreign body.
innammiion in guirH pigs and rabbiæ. Toxlcot Pathot. 2û{;91:321-OZS. - V
74. Jubb RW; Pr./a S, Beinât L, Dâcre J, Gishen P A one-year, randomised, placebo
{saline) conTolled clinicâl triâl of 500-730 kDa sodium hyalurcnate (Hyalgan)
on the radiological change in osteoarthritis of the knee. lnt J Clin Pract.
2ffi3;57:.467-474.
75.FweroL- Pasquali Ronchetti l. Intra-articulartreatment of osteoarlhritis-of the
knee: an arthroscopic and clinical compâiso{] betvveen sodium hyaluronate
{500-730 kDa) and methylprednisone acêtâto. J Orthop Traumatol
2002;3:89-96.
v